Pharmacologically relevant doses of valproate upregulate CD20 expression in three diffuse large B-cell lymphoma patients in vivo

Table 1 Overview of drug and sampling administration in the VALFRID study

Valproate was administered three times daily day 1–3, prednisone was administered day 1–5 and R-CHO (rituximab, cyclophosphamide, doxorubicin and vincristine) was administered day 3. PBMCs were collected in the morning day 0 and day 3 of the 1st, 3rd and 6th treatment cycles before the R-CHO treatment was administered. Fine needle biopsy was also performed on day 0 and in the morning of day 3 before R-CHO treatment was administered in the 1st treatment cycle of consenting applicable patients.

ISSN: 2162-3619